Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Device Impact on the Efficacy of Serum Product Study

10 november 2026 uppdaterad av: ChinaNorm

The goal of this clinical trial is to learn whether combining a beauty device with the test product affects skin parameters in women troubled by wrinkles. It aims to evaluate the impact of the beauty device on the efficacy of the test product. The main questions it aims to answer are:

- Does the combination of the beauty device plus test product achieve better skin improvement compared with using the test product alone?

Researchers will compare beauty device + test product applied to one half of the face and one side of the neck against the test product alone applied to the contralateral half-face and neck, to see whether the beauty device enhances the efficacy of the test product.

Participants will:

  • Receive randomized split-face and split-neck treatment during the study
  • Attend 10 scheduled study visits
  • Undergo standardized image capture, clinical assessment and instrumental skin measurement

Studieöversikt

Status

Rekrytering

Betingelser

Intervention / Behandling

Studietyp

Interventionell

Inskrivning (Beräknad)

35

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina
        • Rekrytering
        • Shanghai China-norm Quality Technical Service Co., Ltd., Shanghai, Shanghai 200072, Shanghai,
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

25 år till 55 år (Vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Kvinna

Beskrivning

Inclusion Criteria:

  • 1. Chinese female with 25 - 55 years old.
  • 2. All skin types, 50% self-declare sensitive skin.
  • 3. Self- declare with concerns on facial wrinkle problems.
  • 4. The difference in clinical grading between the two sides of the face should be less than one point.
  • 5. Presenting with following certain degree skin qualities clinical grading by dermatologist: Skin radiance, brightness, global appearance of fine lines, elasticity, plumpness, skin firmness: 3≤grade≤6 (refer to 0-9 scale); Crow's feet wrinkles: 2≤ grade (Skin Aging Atlas); Underneath eye wrinkle: 2≤ grade (Skin Aging Atlas); Nasolabial folds:2 ≤ grade (Skin Aging Atlas); Ptosis of the lower part of the face 1≤grade (Skin Aging Atlas);
  • 6. Did not participate any clinical test or cosmetic product test on skin within 3 months.
  • 7. Did not participate any chemical/beauty procedures for previous 6 months.
  • 8. No disagreement of dermatologist because of other reasons that exclude the participation of the subject.
  • 9. Willing and able to participate as evidenced by signing of informed consent and photo release form.
  • 10. Must be willing to comply with all study protocol requirements.

Exclusion Criteria:

  • 1. Pregnant or breast-feeding woman or woman planning pregnancy during the study.
  • 2. Subject deprived of rights by a court or administrative order.
  • 3. Major subject to a guardianship order.
  • 4. Subject residing in a health or social care establishment.
  • 5. Patient in an emergency setting.
  • 6. Subject with a skin disease in the test areas as well as skin allergy (particularly e.g., acne, rosacea, eczema).
  • 7. Subject presenting a stable or progressive serious disease (per investigator's assessment).
  • 8. Immuno-compromised subject.
  • 9. Subject with history of allergy to cosmetic or personal care products or ingredients.
  • 10. Subject presenting excessive exposure to sunlight or UV radiation (investigator's assessment).
  • 11. Subject regularly practicing aquatic or nautical sports.
  • 12. Subject regularly attending a sauna.
  • 13. Subject with physical highly sensitive constitution.
  • 14. Subject with cardiovascular or circulatory history.
  • 15. Subject with a history of skin cancer or malignant melanoma.
  • 16. Intake of antihistamines, antibiotics, corticosteroids, non-steroidal anti-inflammatories or immune- suppressants in the last 6 months before study.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Övrig
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Arm 1

Randomly assigned half-face and half-neck receives the beauty device combined with the test product. The study includes short-term on-site application and long-term home-use regimen.

Short-term: 1.48 g test product applied on half-face & half-neck, massaged by beauty device for about 5 min 50 sec at study site. Long-term: Subjects follow standardized home skincare routine between visits. On-site visits: treatment side receives beauty device and test product.

Aktiv komparator: Arm 2

Contralateral half-face and half-neck receives only the test product without the beauty device, as within-subject control. The same home skincare regimen is followed.

Short-term: 0.45 g test product manually applied on half-face by staff, no beauty device. Long-term: same full-face home skincare routine. On-site visits: only test product is applied on this control side without beauty device treatment.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Dermatologist clinical assessment of skin parameters using modified Griffiths 10-point scale
Tidsram: 2 weeks before baseline, Baseline, 1 hour and 24 hours after product application, 1 hour after product application at Week 1 visit, 1 hour after product application at Week 2 visit,1 hour after product application at Week 3 visit and Week 4 visit.

A dermatologist evaluates skin parameters on the left and right half-face/half-neck separately. Assessments include skin tone, skin quality and wrinkle parameters graded on a 0-9 scale. Half-point (0.5) or incremental values (0.4/0.6) may be used. The rater is blinded to prior scores after baseline.

2 weeks before baseline, Baseline, 1 hour and 24 hours after product application, 1 hour after product application at Week 1 visit, 1 hour after product application at Week 2 visit,1 hour after product application at Week 3 visit and Week 4 visit.

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Stratum corneum hydration measured by Corneometer® CM 825
Tidsram: Baseline, Week1 visit, Week2 visit, Week3 visit, Week4 visit

Skin hydration is measured bilaterally on cheeks using Corneometer® CM 825 (capacitance method). The mean value of 3 consecutive valid readings is recorded; higher values indicate greater hydration.

Baseline, Week1 visit, Week2 visit, Week3 visit, Week4 visit
Transepidermal water loss (TEWL) measured by Vapometer
Tidsram: Baseline, Week1 visit, Week2 visit, Week3 visit, Week4 visit

TEWL is measured bilaterally on cheeks using Vapometer. One reading is taken per site. Unit: g/m²h; lower values indicate better skin barrier function.

Baseline, Week1 visit, Week2 visit, Week3 visit, Week4 visit
wrinkle analysis using Antera 3D
Tidsram: Baseline, 1 hour after product application, Week3 (1 hour after product application at Week3 visit), Week4

Antera 3D generates 3D colour images of skin surface by analysing shadow and light reflection. Standard wrinkle photographs are captured and analysed.

Baseline, 1 hour after product application, Week3 (1 hour after product application at Week3 visit), Week4
Skin texture analysis using VisioScan VC20
Tidsram: Baseline, 1 hour and 24 hours after product application, Week1 (visit and 1h post-application), Week2 (visit and 1h post-application), Week3 (visit and 1h post-application), Week4

VisioScan VC20 (UV CCD imaging probe) captures skin images on bilateral cheeks and neck. Images are processed and analysed by SELS software to evaluate skin smoothness.

Baseline, 1 hour and 24 hours after product application, Week1 (visit and 1h post-application), Week2 (visit and 1h post-application), Week3 (visit and 1h post-application), Week4

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
3D facial imaging using Vectera-H2
Tidsram: Baseline, 1 hour after product application, Week3 (1 hour after product application at Week3 visit), Week4

Handheld Vectera-H2 captures 180° stereophotogrammetric 3D facial images. Assessment endpoint: facial fullness.

Baseline, 1 hour after product application, Week3 (1 hour after product application at Week3 visit), Week4
Facial imaging acquisition using VISIA®-CR (Canfield)
Tidsram: Baseline, 1 hour and 24 hours after product application, Week1 (visit and 1h post-application), Week2 (visit and 1h post-application), Week3 (visit and 1h post-application), Week4

Facial images are captured by trained staff with VISIA®-CR, equipped with multiple light sources (standard, cross-polarized, parallel polarized, oblique, UV). Images are taken from left, central and right views with subject wearing hairnet and eyes closed.

Baseline, 1 hour and 24 hours after product application, Week1 (visit and 1h post-application), Week2 (visit and 1h post-application), Week3 (visit and 1h post-application), Week4

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

23 september 2026

Primärt slutförande (Faktisk)

10 november 2026

Avslutad studie (Beräknad)

30 november 2026

Studieregistreringsdatum

Först inskickad

10 november 2026

Först inskickad som uppfyllde QC-kriterierna

10 november 2026

Första postat (Faktisk)

16 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

16 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

10 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • C26005101

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .